Peptides, GLP-1s, and the Future of Bio-Writing
An analysis of the shift from passive health monitoring to active biological intervention. This brief covers the market expansion of GLP-1 drugs, the rise of gray-market peptides, and the emerging investment opportunities in neurotechnology and real-time biomarker sensing.
The Paradigm Shift in Consumer Health
The health and wellness sector is undergoing a fundamental transformation, moving from passive monitoring to active biological intervention. Dr. Andrew Huberman and A16Z partner Daisy Wolf discuss how the pandemic accelerated consumer autonomy, shifting focus from traditional medical reliance to self-directed health optimization. This shift has created a robust market for supplements, peptides, and neurotechnology, driven by a desire for direct control over physiological states.
GLP-1s and the Peptide Economy
The proliferation of GLP-1 drugs has redefined obesity treatment, with nearly one in seven Americans currently using these agents. The market is expanding beyond pharmaceutical channels into compounding pharmacies and gray markets, where lower-cost alternatives and experimental peptides like BPC-157 and retatrutide are circulating. While this democratizes access, it introduces significant safety risks, including contamination and unverified efficacy. The distinction between regulated gray-market sources and unregulated black-market products is critical for consumer safety and regulatory compliance. As next-generation drugs like retatrutide approach approval, the potential to eradicate obesity becomes a tangible economic and social reality, though muscle preservation remains a key clinical challenge.
From Reading to Writing Biology
The next frontier in health tech is the transition from "reading" biology via wearables to "writing" to it through direct intervention. Current technologies primarily monitor metrics like sleep and glucose, but the future lies in non-invasive neurotechnology that can actively modulate physiological states. This includes devices that cool the core body temperature to induce sleep, eye masks that stimulate REM cycles, and sensors that track real-time cortisol levels. The ability to dial in cognitive states, such as focus and alertness, without the side effects of stimulants, represents a high-value investment opportunity.
Strategic Implications for Investors
Investors should focus on companies developing multi-biomarker sensors, particularly for cortisol, which is currently a blind spot in consumer health monitoring. Additionally, the market for safer cognitive enhancers that do not rely on the sympathetic nervous system is underserved. The convergence of AI and biological data will likely lead to personalized health protocols, but the mechanism of action remains crucial for consumer adoption. Understanding the biological basis of health interventions increases the probability of behavioral change, suggesting that education and mechanism-focused marketing will be key drivers of success in this space. The future of health is not just about extending life, but about optimizing the quality and functionality of the years we live.
Key insights
-
GLP-1 drugs are transitioning from niche treatments to mainstream metabolic interventions, with significant market penetration and anticipated expansion through next-generation agents like retatrutide. This shift is driven by both pharmaceutical innovation and consumer demand for accessible weight management solutions.
Impact: Creates a massive addressable market for obesity treatment, with opportunities in drug development, compounding pharmacy services, and related health services.
-
The gray market for peptides is growing rapidly, with consumers seeking lower-cost alternatives to pharmaceutical drugs. This market operates in a regulatory vacuum, creating both opportunities for innovation and significant risks regarding product safety and efficacy.
Impact: Requires careful navigation of legal and safety boundaries; companies that can provide verified, safe peptide sources will have a competitive advantage.
-
The health tech industry is shifting from passive data collection to active physiological intervention, known as "writing to biology." This involves using technology to directly modulate sleep, focus, and stress levels rather than just monitoring them.
Impact: Opens new investment opportunities in neurotechnology and wearable devices that can actively improve health outcomes, moving beyond simple tracking.
-
Real-time cortisol sensing is a critical gap in current health monitoring technologies. While glucose monitoring is widespread, the lack of accessible tools to track stress hormones limits the ability to manage mental health and metabolic function effectively.
Impact: Developing reliable, non-invasive cortisol sensors could unlock new markets in preventive mental health and longevity, addressing a major unmet need.
-
Consumer behavior is shifting towards self-directed health management, driven by a desire for control over physiological states. This is evident in the popularity of supplements, peptides, and neurotechnology, reflecting a broader trend of autonomy in health care.
Impact: Brands and platforms that empower consumers with actionable, mechanism-based health advice will see higher engagement and loyalty.
Action items
-
Invest in companies developing next-generation GLP-1 drugs and related metabolic therapies. Focus on agents that offer muscle preservation and reduced side effects, as these will be key differentiators in the market.
Impact: Positions investors to capture value in the rapidly expanding obesity treatment market, with potential for high returns as these drugs become mainstream.
-
Develop or partner with entities that provide verified, safe peptide sources. Establish clear protocols for sourcing and testing to mitigate the risks associated with gray-market products.
Impact: Builds trust with consumers and regulators, creating a sustainable business model in a high-risk, high-reward market.
-
Explore investment opportunities in non-invasive neurotechnology that can actively modulate physiological states. Focus on devices that improve sleep, focus, and stress management without relying on stimulants.
Impact: Taps into the emerging market for "writing to biology," offering a novel value proposition that differentiates from traditional health wearables.
-
Fund research and development for real-time cortisol sensors. Collaborate with biotech firms to create accessible, non-invasive tools that track stress hormones in real time.
Impact: Addresses a critical gap in health monitoring, enabling better management of mental health and metabolic function, and opening new market segments.
-
Create educational content and marketing strategies that emphasize the mechanism of action for health interventions. Provide consumers with a clear understanding of how specific behaviors and products affect their biology.
Impact: Increases consumer adoption and loyalty by building trust through transparency and scientific rigor, differentiating brands in a crowded market.
Quotes
“nearly one in seven Americans is taking a GLP one drug. 20% have tried them.”
“we may be approaching the point where we stop just reading our biology through wearables and start writing to it using neurotechnologies that control sleep, focus, and cortisol directly.”
“I think in five years, you and I are gonna have a little cocktail. It's gonna be one injection or one pill, and it's gonna be a little bit of pineal in at night combined with something else.”